GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

The following is a summary of “Sodium-glucose cotransporter 2 inhibitors and glaucoma in patients with type 2 diabetes,” ...

Embargoed until 4 a.m. CT/5 a.m. ET, Monday, Nov. 11, 2024 DALLAS, Nov. 11, 2024 — GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 ...

Type 1 diabetes (also known as diabetes mellitus) is an autoimmune disease in which immune cells attack and destroy the insulin-producing cells of the pancreas. The loss of insulin leads to the ...

"In the emulated clinical trial, the use of SGLT2 inhibitors compared to DPP4 inhibits was linked to significantly lower ...

Among patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitor use was linked to reduced risk for neurodegenerative disorders. Sodium-glucose cotransporter 2 (SGLT2) inhibitor use ...

From 2010 to 2023, there was an increase in prescribing of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium glucose cotransporter 2 (SGLT2) inhibitors among individuals with type 1 ...

and sodium glucose cotransporter 2 (SGLT2) inhibitors among individuals with type 1 diabetes (T1D), according to a research letter published online October 23 in the Journal of the American ...

Previous research had shown that SGLT2 inhibitors decreases all-cause mortality among patients with type 2 diabetes, but it has been unclear whether this benefit extends to older patients with ...

Of note, a similar proportion of patients in the empagliflozin and placebo groups (43% and 40%, respectively) were using an SGLT2 inhibitor ... Subgroups, including by diabetes mellitus and ...

MONDAY, Oct. 28, 2024 (HealthDay News) — From 2010 to 2023, there was an increase in prescribing of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium glucose cotransporter 2 (SGLT2) ...

Differentiating between an irrational versus a rational fear of hypoglycemia has treatment implications and presents significant challenge for clinicians facing patients with type 1 diabetes ... Do ...